Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00961233 · ClinicalTrials.gov registry record · NA
Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00961233 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 25 participants.
The verdict
NCT00961233, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to conduct a clinical trial of two formulations of budesonide (nebulized/swallowed versus viscous/swallowed) in patients with EoE to determine if medication contact time and distribution in the esophagus relates to treatment response. The investigators will also determine if there is systemic absorption of these topical steroids. The investigators hypothesize that tissue and symptom response will correlate with esophageal medication contact time and distribution, and that significant systemic absorption will not be seen.
Interventions
- DRUG inhaled/swallowed budesonide
- DRUG viscous/swallowed budesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00961233
The ClinicalTrials.gov registry entry for NCT00961233 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which inhaled/swallowed budesonide is the first listed.
NCT00961233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00961233 about?
NCT00961233 is a clinical study titled "Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)". The purpose of this study is to conduct a clinical trial of two formulations of budesonide (nebulized/swallowed versus viscous/swallowed) in patients with EoE to determine if medication contact time and distribution in the esophagus relates to treatment response. The investigators will also determin...
What is the current status of trial NCT00961233?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2009-10. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00961233?
The interventions under investigation include: inhaled/swallowed budesonide (DRUG), viscous/swallowed budesonide (DRUG).
Who is sponsoring clinical trial NCT00961233?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.